CAR T Persistence, Aging “Tissue Clocks,” and the Real-World Drivers of Health

Public health is often pictured as prevention campaigns and vaccines. But this week’s research shows a wider system: long-term biology after advanced therapies, new ways to measure aging in tissues, and strong evidence that daily life—what people can afford and what policies protect—shapes health outcomes far beyond clinics. Below are five studies that, together, highlight a key theme: health outcomes are shaped by time. They unfold over years in the body, over decades across populations, and over policy cycles across communities. –

How Long Do CAR T Cells Last? Up to 10 Years in B Cell Lymphomas

A Nature Medicine study found that CAR T cells used to treat non-Hodgkin lymphoma can remain active in the body for up to 10 years after treatment. Researchers followed 38 patients who received CD19 CAR T-cell therapy and found evidence of the engineered cells in several long-term responders more than five years later.

In some patients, the CAR T cells were still functioning years after treatment. One patient still had CAR T cells circulating 9.3 years after infusion and remained progression-free for more than 10 years. The researchers also found that these cells’ characteristics changed over time, suggesting that a small number of long-lasting CAR T-cell populations may help maintain the treatment’s effects.

CAR T therapy is often thought of as a one-time treatment, but its effects can last for many years. That means health systems need long-term plans to monitor and support patients after treatment. Because CAR T therapy requires specialized expertise and infrastructure, ensuring patients have access to appropriate follow-up care is an important part of making these treatments successful.

New “Tissue Clocks” from Whole-Slide Images: Measuring Aging Where It Happens

A Nature Medicine study suggests that different organs and tissues may age at different rates. Researchers used deep learning to analyze more than 25,000 tissue images from 983 people and created “tissue clocks” that estimate the biological age of different parts of the body.

The estimates were connected to other signs of aging, including shorter telomeres, underlying health problems, and chronic conditions. Researchers also found that some tissues appeared to age faster than expected based on a person’s chronological age, with differences associated with lifestyle, demographic, and medical factors. They also developed a method that could potentially estimate the biological age of specific tissues using a blood sample.

The researchers tested the approach in people with eight common diseases, including Alzheimer’s disease, stroke, and Crohn’s disease, and found patterns of accelerated aging in disease-related organs.

Tracking how quickly individual organs are aging could eventually help identify people at risk for disease earlier and allow prevention efforts to be better targeted. A blood test that provides information about aging across different organs could also make this type of monitoring easier to use at scale. However, the approach is still experimental and is not yet ready for routine clinical use.

Affordability and Death: County-Level Evidence Links Less Affordability to Higher Mortality

A U.S. study found that people living in less affordable counties have higher death rates. Researchers compared the cost of basic necessities, such as housing, food, and childcare, with all-cause mortality across more than 3,100 counties.

The pattern remained even after researchers accounted for factors such as income, education, health insurance, race and ethnicity, age, and whether counties were urban or rural. Men living in the least affordable counties had about 89 more deaths per 100,000 people than those in the most affordable counties. Among women, the difference was about 47 additional deaths per 100,000. Similar patterns were found among working-age adults.

Affording housing, food, childcare, and other necessities may affect health and longevity. High costs can affect financial stability, stress, nutrition, and access to healthcare and other resources. The findings suggest that affordability should be considered a potential social determinant of health, shaped not only by individual income but also by wages, housing costs, public benefits, and other policies.

Policy Signals for Cardiovascular Health: Smoking Laws Stand Out, Evidence Varies for Other Supports

A systematic review in the American Journal of Preventive Medicine examined whether social policies can reduce cardiovascular disease. Researchers reviewed 46 U.S. studies covering policies related to smoking, housing assistance, food assistance such as SNAP, and air pollution.

The clearest evidence was for smoking-related laws, which were consistently associated with lower rates of cardiovascular disease. The evidence for housing and food assistance was mixed, while only one study examined air pollution regulations. Many of the studies were observational, making it difficult to determine whether the policies themselves directly caused changes in health.

Policies outside the healthcare system can strongly affect heart health. Smoking laws provide particularly strong evidence that changing the environments in which people live can reduce cardiovascular risk. For housing and food assistance, the findings are less certain—not necessarily because these policies do not improve health, but because better research is needed to understand their effects and who benefits most.

One More System Lesson: Selenium Supplements and Long-Term Risks May Differ from Hopes

A long-term follow-up of the SELECT trial raises questions about the potential health effects of selenium supplements. The original trial tested whether selenium, vitamin E, or both could prevent cancer. It was stopped early after the supplements failed to provide the expected benefits and raised concerns about possible harms.

Researchers have now followed participants for many more years. Selenium supplementation was not associated with increased risk of several conditions, including lung cancer, leukemia, non-Hodgkin lymphoma, and Parkinson’s disease. It was associated with lower rates of melanoma and colorectal cancer, but higher rates of Hodgkin lymphoma, multiple myeloma, and ALS. However, some of these findings were based on relatively few cases and should be interpreted cautiously.

Supplements marketed or used for disease prevention are not automatically harmless. Their effects may take years to become clear, making long-term monitoring important. The findings reinforce the need for careful testing of supplement claims and clear communication about both potential benefits and risks, particularly when evidence remains uncertain.

The Bottom Line

Health Is a System That Works Across Time: From CAR T cells persisting up to 10 years, to tissue clocks that may quantify organ aging, to county affordability shaping mortality, this week’s studies point in the same direction: public health outcomes are the product of biology, environment, and policy—playing out over time.

f you’re wondering what to do with that insight, the practical answer is systems thinking: plan for long-term follow-up, build better monitoring tools, and treat affordability and policy protections as health infrastructure—not background conditions.